Emil D Kakkis sold $4.2M of RARE
President & CEO at Ultragenyx Pharmaceutical Inc.. 98,434 shares at an average of $42.20, traded Feb 28, 2025, filed Mar 4, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.2M at market
- 0Share of holdings soldSold 4.5% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-032779, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2025 | AGrant or award Common Stock10b5-1 | +43,268 | $0.00 | $0 | 607,873 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Common Stock10b5-1 | +107,292 | $0.00 | $0 | 715,165 | Mar 4, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -73,434 | $42.10 | $3.1M | 641,731 | Mar 4, 2025 |
| Feb 28, 2025 | SOpen-market sale Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -25,000 | $42.48 | $1.1M | 2,158,985 | Mar 4, 2025 |
| Mar 1, 2025 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +78,448 | $0.00 | $0 | 78,448 | Mar 4, 2025 |
Related signals
Other insiders at Ultragenyx Pharmaceutical Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $17k 1,283 shares | -2% | |
| 15Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $2,252 161 shares | -0% | |
| 20Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $29k 762 shares | -1% | |
| 45Moderate | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $72k 1,785 shares | -2% | |
| 51Moderate | Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $377k 8,945 shares | -11% | |
| 55Moderate | Ultragenyx Pharmaceutical Inc. | Erik Harris EVP & Chief Commercial Officer | $636k 15,103 shares | -15% | |
| 36Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $41k 967 shares | -2% | |
| 43Moderate | Ultragenyx Pharmaceutical Inc. | Thomas Richard Kassberg CBO & EVP | $254k 6,028 shares | -2% | |
| 23Weak | Ultragenyx Pharmaceutical Inc. | Emil D Kakkis President & CEO | $495k 11,727 shares | -1% | |
| 21Weak | Ultragenyx Pharmaceutical Inc. | Emil D Kakkis President & CEO | $414k 8,273 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.